Contribute Try STAT+ Today

A former Mylan information technology executive pleaded guilty to an insider trading scheme in which he acted on tips from another executive ahead of public announcements about earnings, drug approvals, and a pending merger with a Pfizer (PFE) division.

In court documents, the U.S. Securities and Exchange Commission alleged that Dayakar Mallu, 51, was tipped by an unnamed senior manager at Mylan and acted on the information four separate times between September 2017 and July 2019. In exchange for the inside information, the former Mylan executive shared a portion of the profits with the manager through cash transactions in India.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment